Safety Demonstrated
For the TAXUS I Randomized Feasibility Trial data in portable document format (PDF),
click here.
| Objective: |
Compare safety of Paclitaxel-Eluting NIR® Stent to uncoated control NIR® Stent. |
| Number of Patients: |
61 |
| Number of Sites: |
3 |
| Lesion Type: |
de novo, 3.0 and 3.5 mm |
| Stent Platform: |
NIR® Conformer 15 mm |
| Release Kinetics: |
Slow |
| Primary Endpoint: |
30-day MACE |
| Principal Investigator: |
E. Grube, M.D |
| Status: |
Enrollment complete
|
NIR is a registered trademark of Medinol, Ltd. Jerusalem, Israel.
